GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sandoz Group AG (OTCPK:SDZNY) » Definitions » Operating Margin %

Sandoz Group AG (Sandoz Group AG) Operating Margin % : 3.76% (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Sandoz Group AG Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Sandoz Group AG's Operating Income for the three months ended in Dec. 2023 was $375 Mil. Sandoz Group AG's Revenue for the three months ended in Dec. 2023 was $9,979 Mil. Therefore, Sandoz Group AG's Operating Margin % for the quarter that ended in Dec. 2023 was 3.76%.

The historical rank and industry rank for Sandoz Group AG's Operating Margin % or its related term are showing as below:

SDZNY' s Operating Margin % Range Over the Past 10 Years
Min: 3.76   Med: 8.54   Max: 13.31
Current: 3.76


SDZNY's Operating Margin % is ranked worse than
57.31% of 1019 companies
in the Drug Manufacturers industry
Industry Median: 6.84 vs SDZNY: 3.76

Sandoz Group AG's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Sandoz Group AG's Operating Income for the three months ended in Dec. 2023 was $375 Mil.


Sandoz Group AG Operating Margin % Historical Data

The historical data trend for Sandoz Group AG's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sandoz Group AG Operating Margin % Chart

Sandoz Group AG Annual Data
Trend Dec22 Dec23
Operating Margin %
13.31 3.76

Sandoz Group AG Quarterly Data
Dec22 Dec23
Operating Margin % 13.31 3.76

Competitive Comparison of Sandoz Group AG's Operating Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Sandoz Group AG's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sandoz Group AG's Operating Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sandoz Group AG's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Sandoz Group AG's Operating Margin % falls into.



Sandoz Group AG Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Sandoz Group AG's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=375 / 9979
=3.76 %

Sandoz Group AG's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=375 / 9979
=3.76 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sandoz Group AG  (OTCPK:SDZNY) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Sandoz Group AG Operating Margin % Related Terms

Thank you for viewing the detailed overview of Sandoz Group AG's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sandoz Group AG (Sandoz Group AG) Business Description

Traded in Other Exchanges
Address
Forum 1, Novartis Campus, Basel, CHE, CH-4056
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006 as well as U.S.'s first biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in pipeline.

Sandoz Group AG (Sandoz Group AG) Headlines

From GuruFocus

Q3 2023 Sandoz Group AG Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q3 2023 Sandoz Group AG Earnings Call Transcript

By GuruFocus Research 02-14-2024